This is the authors' abstract. We don't add key points for this paper.
Hematological cancers such as leukemia, lymphoma, and multiple myeloma have traditionally been treated with chemo and radiotherapy approaches. Introduction of immunotherapies for treatment of these diseases has led to patient remissions that would not have been possible with traditional approaches. In this critical review we identify main disease characteristics, symptoms, and current treatment options. Five common immunotherapies, namely checkpoint inhibitors, vaccines, cell-based therapies, antibodies, and oncolytic viruses, are described, and their applications in hematological cancers are critically discussed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lanier et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: